Global Orthobiologics Market Valued $5.4 Bn In 2021 Anticipated To Grow At 7% CAGR By 2026

Orthobiologics uses biomaterials and cell-based therapies to heal musculoskeletal injuries quickly and support tissue healing and restoration through their regenerative potential. These Orthobiologics Market products are derived from components that are naturally present in the body and interact dynamically with the musculoskeletal system to facilitate the healing of bone, cartilage, ligament, and diseased or injured meniscus & tendons.

The Global Orthobiologics Market valued at $5.4 billion (2021) is set to witness a growth rate of 7% in the next 5 years. Increasing geriatric and obese populations globally, an increase in the number of people suffering arthritis and other spine-related disorders, an increase in patient preference for minimally invasive procedures, and mechanical advancements in biomaterials are some of the main reasons propelling the global orthobiologics market.

Technological Advancements In Orthobiologics Market

The development of effective products with enhanced patient healing capacities and expanded applications, among other things, has been made possible by continuous advancements in orthobiologics. As a result, key companies are constantly focusing on investing in research activities for the development of new products and increasing their geographic reach to strengthen their positions in the orthobiologics market. Such advances tend to provide manufacturers with a competitive edge.

Below is a list of a few technological developments:

• In June 2022, Istos Biologics launched the Influx Fibrant line of 100% cortical allograft products featuring a patented technology from TheraCell and designed to advance patient healing
• In March 2022, SeaSpine launched new orthobiologic products- NorthStar cervical facet fusion and Flash navigation lumbar facet fusion, with an aim to streamline reproducible procedural workflow while maximizing the area for fusion
• In September 2020, Cerapedics received approval for its i-FACTOR+ Matrix bone graft from Health Canada. This next-generation bone graft is based on P15 osteogenic cell-binding peptide that supports bone growth through cell attraction, attachment, and activation

Explore Premium Report on Orthobiologics Market.

Key Growth Strategies Adopted By Leading Market Players

Leading Market players operating in the orthobiologics market have accepted acquisition and partnership as key growth strategies to increase their product offerings, improve their geographic presence & distribution capabilities, and to co-develop advanced products.

Some of these developments are listed below –

• In August 2022, Orthofix Medical Inc. entered into a strategic partnership with CGBio, a synthetic bone grafts developer, to co-develop and commercialize Novosis recombinant human bone morphogenetic protein-2 (rhBMP-2) bone growth materials and other tissue regenerative solutions for the Canadian and US markets
• In July 2021, Celularity Inc. and Arthrex, Inc. entered into a supply and distribution agreement for the distribution and commercialization of multiple products including placental-derived biomaterial products from Celularity for orthopaedics and sports medicine in the US
• In March 2021, SeaSpine Holdings Corporation entered an agreement to acquire 7D Surgical, Inc., a Canada-based medical device company. This acquisition was aimed at combining spinal implant and orthobiologics portfolios to advance spine surgery

Irrespective of the challenges such as unfavorable reimbursement scenarios and pricing pressure on market players, the global orthobiologics market is expanding and is anticipated to gain further momentum in the coming years due to a strong emphasis on the spinal fusion segment, focus on demineralized bone putties with excipients, growing usage of viscosupplements, and innovations addressing the entire procedure, among others.

For instance, during the forecast period, advances in hyaluronic acid-based therapies, rising prevalence of lifestyle-induced disorders, high efficacy in delaying total knee replacement procedures, and growing preference for non-surgical treatments for osteoarthritis are expected to drive the viscosupplements segment. Furthermore, conventional techniques such as autograft and allograft are challenging to manage, painful for the patient, have fairly contrasting outcomes, and may require repeat surgeries. Hence, an easier-to-use solution is likely to be accepted by doctors and healthcare providers with a greater success rate from a medical and financial standpoint, providing an opportunity for market players in this space.

Competitive Landscape Analysis

The orthobiologics market is marked by the presence of key players such as Medtronic Plc (Ireland); Zimmer Biomet Holdings, Inc. (US); Arthrex, Inc. (US); Bioventus (US); DePuy Synthes (Johnson & Johnson Services, Inc.) (US); Stryker Corporation (US); MTF Biologics (US); and others.

For More Detailed Insights, Contact Us.

About Medi-Tech Insights

Medi-Tech Insights is a healthcare-focused business research & insights firm. Our clients include Fortune 500 companies, blue-chip investors & hyper-growth start-ups. We have completed 100+ projects in Digital Health, Healthcare IT, Medical Technology, Medical Devices & Pharma Services.

Contact

Ruta Halde

Associate, Medi-Tech Insights

+32 498 86 80 79

info@meditechinsights.com